NCT05473715View on ClinicalTrials.gov

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

July 11, 2023

Study Completion Date

July 11, 2023

Conditions
Neovascular (Wet) Age-related Macular Degeneration
Interventions
DRUG

Aflibercept(BAY86-5321, Eylea)

2mg, intravitreal (IVT) injection

Trial Locations (3)

K2B7E9

Retina Center of Ottawa, Ottawa

J1J 2B8

GOGiunta ophtalmologie, Sherbrooke

BS12LX

Bristol Eye Hospital, Bristol

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05473715 - A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment | Biotech Hunter | Biotech Hunter